ClinicalTrials.gg
RecruitingNCT06920004emvigorateUpdated Nov 16, 2026

A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

A Phase 3 interventional study of empasiprubart and IVIg in Chronic Inflammatory Demyelinating Polyneuropathy, CIDP and CIDP - Chronic Inflammatory Demyelinating Polyneuropathy, sponsored by argenx. Recruiting at 109 sites in 31 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by argenx · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.
Updated Nov 16, 20269 sites added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
218
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States — 20 open to participants now, 25 under way, 10 of them phase 3. Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States.

Planned enrollment
5th of 42
218 · median 74
Started
2025
with 12 others
Phase 3
15 of 55
8 open now
Primary completion
2027-09
later than 10 of 24 live
Registered
46th of 55
by date
Lead sponsor
7 of 55
argenx

Among the 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States, this one is the 5th largest by planned enrollment of the 42 interventional ones that give a count, is one of 13 that started in 2025, is one of 15 in phase 3, reaches primary completion later than 10 of the 24 other live ones, and was the 46th registered.

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

137 studies on the registry are indexed under Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; 50 are open to participants now.

Browse Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies →

Open to participants now

20 of the 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 36 Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies recruiting now, 24 (67%) set no upper age limit and 9 (25%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States, or all of them as a file.
02

Study summary

The main purpose of this study is to compare empasiprubart and IVIg for treating people with CIDP. This study consists of a Part A where participants will either receive empasiprubart and a placebo resembling IVIg, or IVIg and a placebo resembling empasiprubart for 24 weeks (6 months). Following Part A, participants will enter Part B in which all participants will receive empasiprubart for 96 weeks (24 months).

More information can be found here: https://clinicaltrials.argenx.com/emvigorate

03

Conditions studied

  • Chronic Inflammatory Demyelinating Polyneuropathy
  • CIDP
  • CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meets criteria for CIDP based on EAN/PNS Task Force CIDP guidelines, second revision (2021)
  • Has either typical CIDP or 1 of the following CIDP variants: motor CIDP, multifocal CIDP (also known as Lewis-Sumner syndrome), focal CIDP, or distal CIDP
  • Has responded to IVIg in the past 5 years
  • Receiving treatment with IVIg within a standard optimal maintenance dosing regimen, with a minimum weekly IVIg dose of at least 0.125 g/kg
  • Has residual disability and active disease

Exclusion criteria

Exclusion Criteria:

  • Besides the indication under study, known disease or any medical condition that would interfere with an accurate assessment of clinical symptoms of CIDP or puts the participant at undue risk, including polyneuropathy of other causes
  • Meets the criteria for possible or sensory CIDP based on EAN/PNS Task Force CIDP guidelines, second revision (2021)
  • Use of other long-acting immunomodulatory treatment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
218 participants (estimated)

Study arms

  • Experimental
    Part A - empasiprubart + IVIg-placebo

    During Part A, participants receive empasiprubart and a placebo resembling the IVIg treatment in this arm.

    Biological: empasiprubart · Other: IVIg-placebo

  • Active comparator
    Part A - IVIg + empasiprubart-placebo

    During Part A, participants receive IVIg and a placebo resembling the empasiprubart treatment in this arm.

    Biological: IVIg · Other: empasiprubart-placebo

  • Experimental
    Part B - empasiprubart

    After completion of part A, participants can proceed to part B where they receive empasiprubart (no IVIg). Participants from the empasiprubart + IVIg- placebo arm in Part A will receive empasiprubart placebo once to maintain the blind of Part A.

    Biological: empasiprubart · Other: empasiprubart-placebo

Interventions

  • Biologicalempasiprubart

    Intravenous infusion of empasiprubart

  • BiologicalIVIg

    Intravenous infusion of IVIg

  • Otherempasiprubart-placebo

    A placebo resembling the empasiprubart treatment

  • OtherIVIg-placebo

    A placebo resembling the IVIg treatment

06

What researchers measure

Primary outcomes

  1. Reduction of ≥1 point compared with baseline in aINCAT score at week 24

    The Adjusted Inflammatory Neuropathy Cause and Treatment Disability Score (aINCAT) score is a 10-point scale that covers the functionality of legs and arms. The score varies between 0 and 10 (higher score, worse outcome).

    Time frame: up to 24 weeks

Secondary outcomes

  1. Change from baseline in I-RODS centile points score at week 24

    Inflammatory Rasch-built Overall Disability Scale (I-RODS) assesses the limitations of activities and social participation in patients with inflammatory neuropathies like CIDP. The score ranges from 0 to 100 (higher score, worse outcome).

    Time frame: up to 24 weeks

  2. Change from baseline in MRC-SS at week 24

    The Medical Research Council Sum Score evaluates motor strength. Evaluated on 6 muscle groups on each side, the score varies from 0 to 60 (lower score, worse outcome).

    Time frame: up to 24 weeks

  3. Change from baseline in grip strength (3-day moving average) in the dominant hand at week 24

    The grip strength will be measured daily by using a Martin-Vigorimeter. The 3 daily measurements of grip strength from the left hand and the 3 daily measurements of grip strength from the right hand will be recorded, and the daily average for the left hand and right hand will be calculated, respectively. The 3-day moving average will be generated based on the average of the obtained averages for each hand on the target day and the preceding 2 days.

    Time frame: up to 24 weeks

  4. Time to reduction of ≥1 point from baseline in aINCAT score

    The Adjusted Inflammatory Neuropathy Cause and Treatment Disability Score (aINCAT) score is a 10-point scale that covers the functionality of legs and arms. The score varies between 0 and 10 (higher score, worse outcome).

    Time frame: up to 24 weeks

  5. Change from baseline in TUG at week 24

    The Timed Up and Go Test (TUG) is a simple test to assess a person's mobility in which the time expended to rise from a chair, walk 3 meters, turn around, walk back to the chair, and sit down is measured.

    Time frame: up to 24 weeks

  6. Time to increase of ≥1 point compared with baseline in aINCAT score

    The Adjusted Inflammatory Neuropathy Cause and Treatment Disability Score (aINCAT) score is a 10-point scale that covers the functionality of legs and arms. The score varies between 0 and 10 (higher score, worse outcome).

    Time frame: Up to 24 weeks

  7. Change from baseline in grip strength (3-day moving average) of both hands over time

    The grip strength will be measured daily by using a Martin-Vigorimeter. The 3 daily measurements of grip strength from the left hand and the 3 daily measurements of grip strength from the right hand will be recorded, and the daily average for the left hand and right hand will be calculated, respectively. The 3-day moving average will be generated based on the average of the obtained averages for each hand on the target day and the preceding 2 days.

    Time frame: up to 24 weeks + 96 weeks (Part B)

  8. Change from baseline in grip strength (daily average) for both hands

    The grip strength will be measured daily by using a Martin-Vigorimeter. The 3 daily measurements of grip strength from the left hand and the 3 daily measurements of grip strength from the right hand will be recorded, and the daily average for the left hand and right hand will be calculated, respectively. A daily average will be generated based on the average of the obtained averages for each hand.

    Time frame: up to 24 weeks + 96 weeks (Part B)

  9. Change from baseline in MRC-SS over time

    The Medical Research Council Sum Score evaluates motor strength. Evaluated on 6 muscle groups on each side, the score varies from 0 to 60 (lower score, worse outcome).

    Time frame: up to 96 weeks (Part B)

  10. Change from baseline in aINCAT over time

    The Adjusted Inflammatory Neuropathy Cause and Treatment Disability Score (aINCAT) score is a 10-point scale that covers the functionality of legs and arms. The score varies between 0 and 10 (higher score, worse outcome).

    Time frame: up to 24 weeks (Part A) + 96 weeks (Part B)

  11. Change from baseline in EQ-5D-5L over time

    EQ-5D-5L questionnaire is a patient-reported outcome measure, ranging 0 to 100 (lower score, worse outcome).

    Time frame: up to 24 weeks (Part A) + 96 weeks (Part B)

  12. Change from baseline in RT-FSS over time

    Rasch-Transformed Fatigue Severity Scale (RT-FSS) is a patient-reported outcome measure to distinguish fatigue from clinical depression.

    Time frame: up to 24 weeks (Part A) + 96 weeks (Part B)

  13. Change from baseline in SF-12 over time

    12-Item Short Form Health Survey (SF-12) is a general patient-reported outcome measure.

    Time frame: up to 24 weeks (Part A) + 96 weeks (Part B)

  14. Change from baseline in BPI-SF over time

    The Brief Pain Inventory-Short Form (BPI-SF) is a patient-reported outcome measure to assess pain severity and pain interference.

    Time frame: up to 24 weeks (Part A) + 96 weeks (Part B)

  15. PGI-S values over time

    The Patient Global Impression of Severity (PGI-S) is a patient-reported outcome measure that reflects the patient's belief about the severity of the illness.

    Time frame: up to 24 weeks (Part A) + 96 weeks (Part B)

  16. PGI-C values over time

    The Patient Global Impression of Change (PGI-C) is a patient- reported outcome measure that reflects the patient's belief about the efficacy of treatment.

    Time frame: up to 24 weeks (Part A) + 96 weeks (Part B)

  17. Values for work-related and household chore activities of the HRPQ

    The Health-Related Productivity Questionnaire (HRPQ) assesses health-related and work-related productivity, with questions related to 'hours lost because of absenteeism'.

    Time frame: up to 24 weeks

  18. Percentage of scheduled hours lost in total (absenteeism+ presenteeism)

    Time frame: up to 24 weeks

  19. Change from baseline in I-RODS centile points score over time

    Inflammatory Rasch-built Overall Disability Scale (I-RODS) assesses the limitations of activities and social participation in patients with inflammatory neuropathies like CIDP. The score ranges from 0 to 100 (higher score, worse outcome).

    Time frame: Up to 96 weeks (Part B)

  20. Change from baseline in TUG over time

    The Timed Up and Go Test (TUG) is a simple test to assess a person's mobility in which the time expended to rise from a chair, walk 3 meters, turn around, walk back to the chair, and sit down is measured.

    Time frame: Up to 96 weeks (Part B)

  21. Incidence of antidrug antibodies against empasiprubart in serum

    Time frame: up to 24 weeks (Part A) + 96 weeks (Part B)

  22. Incidence of neutralizing antibodies against empasiprubart in serum

    Time frame: up to 24 weeks (Part A) + 96 weeks (Part B)

  23. Incidence of (serious) adverse events

    Time frame: up to 24 weeks (Part A) + 96 weeks (Part B)

  24. Percentage change from baseline in free C2 and total C2 over time

    Time frame: up to 24 weeks (Part A) + 96 weeks (Part B)

  25. Serum concentrations of empasiprubart over time

    Time frame: up to 24 weeks (Part A) + 96 weeks (Part B)

07

Study locations

109 of 109 sites recruiting

Showing the first 100 of 109 sites across 31 countries. Choose a country and city above to see the rest.

08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Sep 2027, 25 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2025
First posted
Apr 9, 2025
StartActual
Aug 22, 2025
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2030
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
9 sites added, 1 site removed
Show 9 added (3 United States, 2 Brazil, 1 Spain, 1 Israel, 1 Canada, 1 Turkey (Türkiye))
  • Hospital de La Santa Creu i Sant Pau · Barcelona, Spain
  • University Neurology · Knoxville, United States
  • The Chaim Sheba Medical Center · Tel HaShomer, Israel
  • Banner University of Arizona Medical Center · Tucson, United States
  • Escola Bahiana de Medicina e Saude Publica · Salvador, Brazil
  • University of Alberta · Edmonton, Canada
  • Istanbul Tip Fakultesi Hastanesi (Istanbul Universitesi) · Istanbul, Turkey (Türkiye)
  • University of North Carolina Hospital · Chapel Hill, United States
  • Hospital Moinhos de Vento · Porto Alegre, Brazil
Show 1 removed
  • The Chaim Sheba Medical Center · Tel Litwinsky, Israel
across 4 updates, Oct 16, 2026 – Nov 16, 2026
Show all 4 updates
  1. Nov 16, 2026
    2 sites added
    Show 2 added (1 United States, 1 Brazil)
    • University of North Carolina Hospital · Chapel Hill, United States
    • Hospital Moinhos de Vento · Porto Alegre, Brazil
  2. Nov 3, 2026
    4 sites added
    Show 4 added (1 United States, 1 Brazil, 1 Canada, 1 Turkey (Türkiye))
    • Banner University of Arizona Medical Center · Tucson, United States
    • Escola Bahiana de Medicina e Saude Publica · Salvador, Brazil
    • University of Alberta · Edmonton, Canada
    • Istanbul Tip Fakultesi Hastanesi (Istanbul Universitesi) · Istanbul, Turkey (Türkiye)
  3. Oct 30, 2026
    2 sites added, 1 site removed
    Show 2 added (1 United States, 1 Israel)
    • University Neurology · Knoxville, United States
    • The Chaim Sheba Medical Center · Tel HaShomer, Israel
    Show 1 removed
    • The Chaim Sheba Medical Center · Tel Litwinsky, Israel
  4. Oct 16, 2026
    1 site added
    Show site
    • Hospital de La Santa Creu i Sant Pau · Barcelona, Spain

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06920004
Lead sponsor
argenx
Responsible party
Sponsor
First posted
Apr 9, 2025
Start date
Aug 22, 2025
Primary completion
Sep 2027 (estimated)
Completion
Sep 2030 (estimated)
Last update
Nov 16, 2026

Study contacts

Sabine Coppieters, MD
Contact
clinicaltrials@argenx.com
857-350-4834

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empasiprubart

Start the discussion